|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 2 | Hermes:DataWeb search on a pay-as-you-go integration infrastructure显示文摘 | Tran T Haofen W Peter H | 2009 | Web Semantics:Science Services and Agents on World Wide Web2009，7，3： | 1 |
| 3 | Fibroids and reproductive outcomes: a systematic literature review from conception to delivery显示文摘 | Peter C. Klatsky Nam D. Tran Aaron B. Caughey Victor Y. Fujimoto | 2008 | American Journal of Obstetrics and Gynecology2008，，4： | 1 |
| 4 | Clinical, epidemiological and virological features of dengue virus infections in vietnamese patients presenting to primary care facilities with acute undifferentiated fever显示文摘 | Khoa T.D. Thai Hoang Lan Phuong Tran Thi Thanh Nga Phan Trong Giao Le Quoc Hung Nguyen Van Nam Tran Quang Binh Cameron Simmons Jeremy Farrar Tran Thinh Hien H. Rogier van Doorn Menno D. de Jong Peter J. de Vries | 2010 | Journal of Infection2010，，： | 1 |
| 5 | Anthropometric correlates of intragastric pressure显示文摘 | Hashem B. El-Serag Thomas Tran Peter Richardson Gulchin Ergun | 2006 | Scandinavian Journal of Gastroenterology2006，，8： | 1 |
| 6 | Development of a high cell-density fed-batch bioprocess for the heterolo- gous production of 6-deoxyerythronolide B in Escherichia coli 显示文摘 | Janice Lau Carnie Tran Peter Licari | 2004 | Journal of Biotechnology2004，，110： | 1 |
| 7 | In vivo endoscopic optical coherence tomography by use of a rotational microelectromechanical system probe 显示文摘 | Peter H Tran David S Mukai Matthew Brenner | 2004 | Opics Letters2004，29，11： | 1 |
| 8 | Ordinal scale based description of colour rendering 显示文摘 | Bodrogi Peter Stefan Brtickner Tran Quoc Khanh | 2011 | Color Research & Application2011，36，4： | 1 |
| 9 | Magnetic lattices for ultracold atoms and degenerate quantum gases显示文摘We review recent developments in the use of magnetic lattices as a complementary tool to optical lattices for trapping periodic arrays of ultracold atoms and degenerate quantum gases. Recent advances include the realisation of Bose–Einstein condensation in multiple sites of a magnetic lattice of one-dimensional microtraps, the trapping of ultracold atoms in square and triangular magnetic lattices,and the fabrication of magnetic lattice structures with submicron period suitable for quantum tunnelling experiments.Finally, we describe a proposal to utilise long-range interacting Rydberg atoms in a large spacing magnetic lattice to create interactions between atoms on neighbouring sites. | Yibo Wang Prince Surendran Smitha Jose Tien Tran Ivan Herrera Shannon Whitlock Russell Mc Lean Andrei Sidorov Peter Hannaford | 2016 | Science Bulletin2016，61，14： | 1 |
| 10 | Thermal expansion behaviour of aluminum matrix composites with densely packed SiC particles显示文摘 | TRAN HUU NAM GUILLERMO REQUENA PETER DEGISCH- ER | 2008 | Composites:Part A2008，39，： | 1 |
| 11 | Symptomatic Val122del mutated hereditary transthyretin amyloidosis: Need for early diagnosis and prioritization for heart and liver transplantation显示文摘Background: Hereditary transthyretin(ATTRv) amyloidosis is an autosomal dominant disease linked to transthyretin gene mutations which cause instability of the transthyretin tetramer. After dissociation and misfolding they reassemble as insoluble fibrils(i.e. amyloid). Apart from the common Val30 Met mutation there is a very heterogeneous group of non-Val30 Met mutations. In some cases, the clinical picture is dominated by a rapidly evolving restrictive and hypertrophic cardiomyopathy. Methods: A case series of four liver recipients with the highly clinically relevant, rare and particularly aggressive Val122 del mutation is presented. Medical and surgical therapeutic options, waiting list policy for ATTRv-amyloidosis, including the need for heart transplantation, and status of heart-liver transplantation are discussed. Results: Three patients needed a staged(1 patient) or simultaneous(2 patients) heart-liver transplant due to rapidly progressing cardiac failure and/or neurologic disability. Domino liver transplantation was impossible in two due to fibrotic hepatic transformation caused by cardiomyopathy. After a follow-up ranging from 3.5 to 9.5 years, cardiac(allograft) function was maintained in all patients, but neuropathy progressed in three patients, one of whom died after 80 months. Conclusions: This is the first report in(liver) transplant literature about the rare Val122 del ATTRv mutation. Due to its aggressiveness, symptomatic patients should be prioritized on the liver and, in cases with cardiomyopathy, heart waiting lists in order to avoid the irreversible neurological and cardiac damage that leads to a rapid lethal outcome. | Adriano-Valerio Schettini Laura Llado JulieK Heimbach JoseGonzalez Costello Marie Tranäng Olivier Van Caenegem Richard C Daly Peter Van den Bergh Carlos Casasnovas Joan Fabregat John J Poterucha Maxime Foguenne Bo Göran Ericzon Jan Lerut | 2021 | Hepatobiliary & Pancreatic Diseases International2021，20，4： | 1 |
| 12 | Review of fullerene toxicity andexposure-appraisal of a human health risk assessment, based on open literature 显示文摘 | Aschberger K Johnston HJ Stone V Aitken RJ Tran CL HankinSM Peters SAK Christensen FM | 2010 | Regul Toxicol Pharm2010，58，3： | 1 |
| 13 | High-performa-nce lift augmentation dynamic seals for turbine bearing compartments 显示文摘 | Hung Tran Peter Haselbacher | 2004 | Sealing Technology2004，，1： | 1 |
| 14 | Dialkyl imidazolium acetate ionosilica as efficient and recyclable organocatalyst for cyanosilylation reactions of ketones显示文摘We report new heterogeneous organocatalyst based on silica hybrid supported N-heterocyclic carbene(NHC-)species.The organocatalyst is formed from an imidazolium iodide based ionosilica material,followed by iodide/acetate anion exchange.The imidazolium acetate generates the organocatalytic carbene via partial deprotonation of the imidazolium ring in situ.As monitored via EDX,solid state NMR and ion chromatography measurements,the iodide/acetate exchange involving the imidazolium ionosilica material took place only in small extent.Despite the fact that the exchanged material contains only a very small amount of acetate,we observed good catalytic activity and recyclability in cyanosilylation reactions of ketones with trimethylsilyl cyanide.The versatility of the catalyst was highlighted via reaction with several substrates,yielding the corresponding cyanohydrins in good yields.In recycling experiments,the material showed decreasing catalytic activity starting from the third reaction cycle,but high catalytic activity can be regenerated via another acetate treatment.Our work is important as it highlights the possibility to combine carbene chemistry and silica,which are antagonistic at a first glance.We show that imidazolium acetate based ionosilicas are therefore heterogeneous'proto-carbenes',and that there is no need to form strongly basic silica supported NHCs to obtain heterogeneous NHC-organocatalysts.This work therefore opens the route towards heterogeneous and re-usable NHC-organocatalysts from supported ionic liquid imidazolium acetates. | Thanh Tran Duy Alysson Duarte Rodrigues Giang Vo-Thanh Peter Hesemann | 2020 | Green Energy & Environment2020，5，2： | 1 |
| 15 | Development of a high cell-density fed-batch bioprocess for the heterologous production of 6-deoxyerythronolide B in Escherichia coli显示文摘 | Janice Lau Carnie Tran Peter Licari | 2004 | Journal of biotechnology2004，110，： | 1 |
| 16 | High-performance lift augmentation dynamic seals for turbine bearing compartments 显示文摘 | Hung Tran Peter Haselbacher | 2004 | Sealing Technology2004，，1： | 1 |
| 17 | Distribution and genetic diversity of lactic acid bacteria from traditional fermented sausage显示文摘 | Khanh T.M. Tran Bee K. May Peter M. Smooker Thi T.H. Van Peter J. Coloe | 2010 | Food Research International2010，，1： | 1 |
| 18 | Safety of raw meat and shellfish in Vietnam: An analysis of Escherichia coli isolations for antibiotic resistance and virulence genes显示文摘 | Thi Thu Hao Van James Chin Toni Chapman Linh Thuoc Tran Peter J. Coloe | 2008 | International Journal of Food Microbiology2008，，3： | 1 |
| 19 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia显示文摘 | Borje S Andersson Peter F Thall Timothy Madden Daniel Couriel Xuemei Wang Hai T Tran Paolo Anderlini Marcos de Lima James Gajewski Richard E Champlin | 2002 | Biology of Blood and Marrow Transplantation2002，，9： | 1 |
| 20 | Staged hepatectomy for bilobar colorectal hepatic metastases显示文摘 | Mohammad H. Jamal Mazen Hassanain Prosanto Chaudhury Tung T. Tran Stephanie Wong Yasmine Yousef Yelda Jozaghi Ayat Salman Samir Jabbour Eve Simoneau Saleh Al‐Abbad Murad Al‐Jiffry Goffredo Arena Petr Kavan Peter Metrakos | 2012 | HPB2012，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员